CTIC CTI BioPharma Corp.

0.96
+0.04  (+4%)
Previous Close 0.92
Open 0.94
Price To Book 1.74
Market Cap 55,532,023
Shares 57,978,725
Volume 281,124
Short Ratio
Av. Daily Volume 116,430
Stock charts supplied by TradingView

NewsSee all news

  1. CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

    SEATTLE, Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at the 61st American

  2. CTI BioPharma Reports Third Quarter 2019 Financial Results

    SEATTLE, Nov. 4, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019. "We advanced our pacritinib development

  3. CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

    SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released July 9. 2018. Primary endpoint not met.
PIXUVRI - PIX306 Trial
B-cell non-Hodgkin lymphoma
Phase 3 trial initiation announced October 1, 2019 with data due mid-2021. Presentation at ASH December 9, 2019 at 6pm.
Pacritinib - PACIFICA
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. CTI BioPharma Announces Presentations at the 61st American Society of Hematology Meeting

    SEATTLE, Nov. 6, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced four poster presentations and one oral presentation supporting the Company's pacritinib development program at the 61st American

  2. CTI BioPharma Reports Third Quarter 2019 Financial Results

    SEATTLE, Nov. 4, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported its financial results for the third quarter and nine months ended September 30, 2019. "We advanced our pacritinib development

  3. CTI BioPharma Begins Patient Enrollment in PACIFICA Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis Patients With Severe Thrombocytopenia

    SEATTLE, Oct. 1, 2019 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has initiated patient enrollment in the PACIFICA pivotal Phase 3 trial of its investigational myelofibrosis treatment